$0.00
(0.00%
) Quote detailsUSD
$0.00
(0.00%
)At Close (As of Dec 12, 2025)
$14.53M
Market Cap
-
P/E Ratio
-1.39
EPS
$9.84
52 Week High
$2.36
52 Week Low
HEALTHCARE
Sector
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Chemomab Therapeutics Ltd. is a clinical-stage biopharmaceutical firm headquartered in Tel Aviv, Israel, specializing in the development of innovative biological therapies for inflammatory and fibrotic diseases. The company’s lead candidate, CM-101, is a monoclonal antibody that targets critical pathways associated with fibrosis, demonstrating promise across multiple therapeutic indications. Chemomab is dedicated to harnessing its proprietary technology platform to deliver transformative treatments that aim to significantly improve patient outcomes and quality of life, aligning with its mission to meet pressing medical needs in underserved patient populations.
LPTX
KIND
NVDA
WOK
F
KAVL
ADAP
CGC
TLRY
TSLA
AVGO
NIO
PFE
PLTD
ASST
CDE
SNAP
MTSR
FI
APLT
HBAN
CCL
UBER
KO
WULF
SOUN
CAN
EOSE
INTC
MSTR
MU
CX
ASBP
RR
ITUB
PLUG
MDLZ
NVTS
TSM
CLSK
CPNG
SHOT
ZAPP
RXRX
VALE
IVP
HL
ORCL
NBIS
PG
SPR
KMI
C
HOOD
PLTR
CVE
HPQ
HIMS
USB
CSX
LULU
FITB
GM
T
LPTX
KIND
NVDA
WOK
F
KAVL
ADAP
CGC
TLRY
TSLA
AVGO
NIO
PFE
PLTD
ASST
CDE
SNAP
MTSR
FI
APLT
HBAN
CCL
UBER
KO
WULF
SOUN
CAN
EOSE
INTC
MSTR
MU
CX
ASBP
RR
ITUB
PLUG
MDLZ
NVTS
TSM
CLSK
CPNG
SHOT
ZAPP
RXRX
VALE
IVP
HL
ORCL
NBIS
PG
SPR
KMI
C
HOOD
PLTR
CVE
HPQ
HIMS
USB
CSX
LULU
FITB
GM
T